We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
What you need to know before you can place a medical device on the Great Britain market with a UKCA mark.
This guidance explains what rules of origin (RoOs) are and the changes under the Developing Countries Trading Scheme (DCTS).
Frequently asked questions on the Levelling Up Fund Round 2.
How to object to an application to register for UK geographical indication (GI) protection, change or cancel a product specification and how to appeal against a decision.
Find out about geological screening, nuclear facility siting, exclusion criteria, reviewing, groundwater, NIREX and radiation risk.
The Company Names Tribunal practice direction provides the framework for the management of proceedings brought before the Tribunal.
Get help to classify pharmaceutical products used to treat or prevent diseases or ailments (in humans or animals), including comparators used in clinical trials and placebos.
Explains requirements of the Town and Country Planning (Environmental Impact Assessment) Regulations 2017.
The process for the simultaneous review of veterinary medicine submissions by Switzerland’s Swissmedic and the UK's Veterinary Medicines Directorate.
Find out what unacceptable or unreasonable actions are and how we approach them.
The process for the simultaneous review of veterinary medicine submissions by New Zealand’s Ministry for Primary Industries (MPI) and the UK's Veterinary Medicines Directorate.
This page provides information on the outputs and outcomes definitions for the UK Shared Prosperity Fund.
Guidance on the pre-application stage for Nationally Significant Infrastructure Projects.
Upper Tribunal Administrative Appeals Chamber decision by Judge Church on 28 March 2024.
How investigators and sponsors should manage clinical trials during COVID-19
Advises how to take account of and address the risks associated with flooding and coastal change in the planning process.
This summary explains the new £18.6 million fund to pay for the costs of installing an alarm system in residential buildings to replace Waking Watch.
This sets out the assessment and decision-making process for selecting successful bids to the Community Ownership Fund and the internal decisions approved by the Senior Responsible Officer (SRO).
How to use a factorial randomised controlled trial to evaluate your digital health product.
An overview of key points around access agreements between property owners and network operators for the deployment of digital infrastructure.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).